Edwards Lifesciences (NYSE: EW) reported earnings on April 23. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Edwards Lifesciences missed estimates on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue expanded. Non-GAAP earnings per share grew significantly. GAAP earnings per share expanded significantly.

Margins expanded across the board.

Revenue details
 Edwards Lifesciences notched revenue of $496.7 million. The 22 analysts polled by S&P Capital IQ looked for a top line of $518.7 million on the same basis. GAAP reported sales were 8.2% higher than the prior-year quarter's $459.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.72. The 25 earnings estimates compiled by S&P Capital IQ averaged $0.76 per share. Non-GAAP EPS of $0.72 for Q1 were 36% higher than the prior-year quarter's $0.53 per share. GAAP EPS of $1.24 for Q1 were 125% higher than the prior-year quarter's $0.55 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 75.4%, 310 basis points better than the prior-year quarter. Operating margin was 22.0%, 320 basis points better than the prior-year quarter. Net margin was 29.2%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $535.8 million. On the bottom line, the average EPS estimate is $0.81.

Next year's average estimate for revenue is $2.14 billion. The average EPS estimate is $3.28.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 148 members out of 201 rating the stock outperform, and 53 members rating it underperform. Among 60 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 44 give Edwards Lifesciences a green thumbs-up, and 16 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $98.40.

Is Edwards Lifesciences the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.